Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03164512 · ClinicalTrials.gov registry record · Phase 1
The Pharmacokinetics and Pharmacodynamics of Oral and Vaporized Cannabidiol
A Phase 1 study of Cannabidiol Pharmacokinetics, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT03164512 is a Phase 1 study of Cannabidiol Pharmacokinetics that has completed, run by Johns Hopkins University. The registered enrollment target is 19 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03164512, a Phase 1 study of Cannabidiol Pharmacokinetics, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the pharmacokinetics and pharmacodynamics of cannabidiol administered via inhalation and oral ingestion.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Oral or vaporized cannabidiol
Study Locations (1)
Maryland
- Johns Hopkins Behavioral Pharmacology Research Unit - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2020-01-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03164512
The ClinicalTrials.gov registry entry for NCT03164512 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cannabidiol Pharmacokinetics appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03164512 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT03164512 about?
NCT03164512 is a clinical study titled "The Pharmacokinetics and Pharmacodynamics of Oral and Vaporized Cannabidiol". This study will evaluate the pharmacokinetics and pharmacodynamics of cannabidiol administered via inhalation and oral ingestion.
What is the current status of trial NCT03164512?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2018-06-01. Estimated completion is 2020-01-22.
What conditions does trial NCT03164512 study?
This clinical trial studies the following conditions: Cannabidiol Pharmacokinetics.
What interventions are being tested in trial NCT03164512?
The interventions under investigation include: Placebo (DRUG), Oral or vaporized cannabidiol (DRUG).
Who is sponsoring clinical trial NCT03164512?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03164512 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.